SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors react to the FDA's acceptance of their supplemental Biologics License Application for Anktiva, a development the community views as a critical step toward expanding market access for bladder cancer patients. While the long-term outlook remains bullish among supporters who emphasize the company's oncology pipeline and the potential for a short squeeze, many are actively debating the significance of the upcoming PDUFA date and the impact of continued institutional short interest on the stock's price action.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust (SLV) is facing intense volatility as traders debate whether the metals recent pullback is a fundamental shift caused by rising bond yields and a stronger dollar or a temporary shakeout in a long-term bull market. The community is sharply divided between bears calling for further capitulation and long-term bulls viewing the price dip as a strategic entry point amid ongoing supply-demand constraints and industrial demand.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is experiencing a surge in investor interest and bullish momentum following optimistic commentary from the CEO regarding survival data from its REGAL Phase 3 clinical trial. The community is actively discussing the potential for an imminent short squeeze and institutional accumulation as they await the pivotal 80th trial event, with many viewing the company's immunotherapy pipeline as a transformative candidate for future valuation.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Investors are closely watching NVIDIA ahead of its upcoming earnings report, which has become the primary catalyst driving market sentiment and volatility across the tech and semiconductor sectors. Community discussion is heavily focused on potential price swings around the print, with many debating whether the stock will see a 'buy the rumor, sell the news' dip or a significant breakout fueled by persistent AI infrastructure demand.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is facing downward pressure as investors react to leadership changes, including the retirement of its CTO, and a cautious outlook on upcoming growth. While some investors view the current stock price as an oversold buying opportunity supported by strong customer loyalty, the community remains divided over broader consumer spending headwinds and the stock's persistent negative momentum.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSpark is generating significant investor buzz as the community actively debates whether the company's massive power infrastructure and pending hyperscaler deals will spark a major breakout. Market participants are closely watching for a potential short squeeze amid high short interest and speculative positioning ahead of upcoming earnings.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is surging as the community celebrates a significant earnings beat and raised guidance that validates its aggressive store expansion strategy. Investors are actively discussing the stock's potential to become the next dominant fast-casual player, frequently drawing comparisons to Chipotle while shrugging off concerns about its high valuation.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending as the community doubles down on its brand-building initiatives, ranging from IRL products like energy drinks and spices to sports sponsorships. Investors are actively discussing their long-term conviction in the project's ecosystem and its organic growth strategy.

Shake Shack, Inc. engages in the operation and licensing of Shake Shack restaurants which serve burgers, hot dogs, crinkle cut fries, shakes, frozen custard, beer, wine, and related products. The company was founded by Daniel Harris Meyer on September 23, 2014 and is headquartered in New York, NY.

Shake Shack Inc - Ordinary Shares - Class A

Shake Shack is trending due to a wave of positive insider activity, with the CEO and a director recently purchasing thousands of shares, which has bolstered investor confidence. The community is actively discussing this insider buying as a sign of strength while weighing it against broader restaurant sector volatility and varying opinions on the company's valuation.

Klaviyo, Inc. engages in the provision of a SaaS marketing platform. It offers personal ecommerce marketing reinvented for online stores on Shopify, Bigcommerce, and Magento. The company was founded by Andrew Bialecki and Ed Hallen in 2012 and is headquartered in Boston, MA.

Klaviyo Inc - Ordinary Shares - Series A

Klaviyo

Klaviyo is currently sparking intense debate among investors as they weigh strong revenue growth and a new share repurchase program against fears of AI-driven disruption to the marketing automation space. While some see the stock as a prime value opportunity following recent volatility, others remain cautious, highlighting concerns over insider selling and the company's long-term competitive moat.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PTC Q2 Earnings & Revenues Beat on AI-Led ARR Strength, Shares Jump

PTC jumped in pre-market trading after fiscal Q2 2026 revenue rose 22% and AI-driven product demand fueled stronger ARR growth and buybacks.

Simulations Plus Collaborates With Nvidia During AI Drug Modeling Push

Simulations Plus announces an Nvidia deal to accelerate AI drug modeling, but weak growth and momentum metrics raise concerns about the long-term outlook.read more...

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

Simulations Plus, Inc. (Nasdaq: SLP) (Simulations Plus or the Company), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the...

Do Options Traders Know Something About Simulations Plus Stock We Don't?

Investors need to pay close attention to SLP stock based on the movements in the options market lately.

Cadence Q1 Earnings Top Estimates, 2026 Revenue Outlook Raised 

CDNS tops Q1 estimates, launches agentic AI Super Agents, hits a record $8B backlog, and raises its 2026 revenue outlook.

Simulations Plus, Inc. (NASDAQ:SLP) Receives Consensus Rating of "Hold" from Brokerages

Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) has earned a consensus recommendation of "Hold" from the ten research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and t...

Iridium's Q1 Earnings Miss Estimates, Revenues Increase Y/Y

IRDM misses Q1 2026 EPS estimates despite steady service revenue growth, as IoT demand and strategic investments shape its 2026 outlook.

SAP's Q1 Earnings & Revenues Up Y/Y on Cloud Momentum & AI Tailwinds

SAP posts 20% EPS growth in Q1 2026 as cloud and AI momentum drive revenue gains, boosting shares despite macro uncertainty and signaling continued enterprise demand strength.

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

Simulations Plus, Inc. (Nasdaq: SLP) (Simulations Plus or the Company), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded research collaboration with Lonza Group AG (Lonza), a leading contract development and...

Badger Meter's Q1 Earnings & Revenues Miss Estimates, Stock Dips

BMI misses Q1 estimates as sales fall 9% on project delays, but a strong pipeline and UDlive acquisition signal confidence in long-term growth.

Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The firm operates through the Software and Services segment. The Software segment offers software products for pharmaceutical research, development, and commercialization of the firm's products. The Services segment focuses on contracted consulting studies for customers and offers services supporting marketplace insight and medical communications for clinical and commercial drug development. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Durham, NC.

Current Price	$14.10
Prev Close	$13.78
Open	$13.72
Dividend Yield	0.00%
50-Day Moving Average	$13.41
Beta	0.94
Avg. Volume	406,783.05
PE Ratio	-4.51

52-Week High	$34.01
52-Week Low	$11.09
Market Capitalization	$278.43M
EPS (Annual)	-$3.22
Price to Book	2.13
Revenue Per Employee	$371,732.39

SLP
Simulations Plus Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLP News

SLPSimulations Plus Inc.